12:45 PM EDT, 08/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target price to $86 from $179, reflecting a 2.9x multiple of our 2025 sales estimate, a strong discount to INSP's five-year historical forward average due to investor concerns related to the future impact of GLP-1 drugs. We lower our 2025 EPS estimate to $0.85 from $2.26 and 2026's to $1.71 from $3.20. Q2 EPS of (0.12) vs. $0.32, missed consensus by $0.32 despite a top-line beat. Opex was $185.7M in Q2 (+15% Y/Y), due to ongoing investments in the expansion of the U.S. sales organization, patient marketing expenses, and general corporate costs, partially offset by a reduction in R&D. INSP reduced 2025 guidance, now expecting revenue between $900M and $910M (12%-13% vs. 2024), down from $940M to $955M expected previously, due to challenges in the U.S. commercial launch of the new Inspire V system and a slower-than-expected transition from the previous generation product. Our revised opinion is due to the challenges emerging with the U.S. commercial launch of Inspire V and incorporates a further discount to the valuation.